The antiangiogenic agent linomide inhibits tumor necrosis factor-α secretion via inhibition of its synthesis

Prostate

Volumn 29, Issue 3, 1996, Pages 183-190

  Joseph, Ingrid B J K ^a   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; linomide; macrophage; prostate cancer; TNF

Indexed keywords

ROQUINIMEX; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER INHIBITION; IMMUNOPRECIPITATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROCESSING; PROTEIN SYNTHESIS; TUMOR ASSOCIATED LEUKOCYTE;

ANDROGEN ANTAGONISTS; ANIMALS; CELL DIVISION; CELL LINE, TRANSFORMED; CYCLIC AMP; HOMEOSTASIS; HYDROXYQUINOLINES; INTRACELLULAR MEMBRANES; MICE; PROTEIN SYNTHESIS INHIBITORS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029821481     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199609)29:3<183::AID-PROS4>3.0.CO;2-F     Document Type: Article

References (24)

1. Rowe JM, Nilsson BI, Simonsson B: Treatment of minimal residual disease in myeloid leukemia - The immunotherapeutic options with emphasis on linomide (review). Leukemia Lymphoma 11:321-329, 1993.
2. Ichikawa T, Lamb JC, Christensson PJ, Hartley-Asp B, Isaacs JT: The antitumor effect of the quinolene-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 52:3022-3028, 1992.
3. Vukanovic J, Isaacs JT: Human prostate cancer cells are sensitive to programmed (apoptotic) death induced by an antiangiogenic agent, linomide. Cancer Res 55:3517-3520, 1995.
4. Kalland T, Alm G, Stalhandske T: Augmentation of mouse natural killer cell activity by LS2616, a new immunomodulator. J Immunol 134:3956-3961, 1985.
5. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53:1833-1837, 1993.
6. Folkman J: Inhibition of angiogenesis. Semin Cancer Biol 3:89-96, 1992.
7. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
8. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C: Macrophages and angiogenesis. J Leuk Biol 55:410-422, 1994.
9. Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55:1499-1504, 1995.
10. Polverini PJ, Leibovich J: Induction of Neovascularization in vivo and endothelial cell proliferation in vitro by tumor associated macrophages. Lab Invest 51:635-642, 1984.
11. Polverini PJ: Macrophage induced angiogenesis: a review. Cytokines 1:54-73, 1989.
12. Beutler B: The complex regulation and biology of TNF (cachetin). Oncogenesis 2:9-18, 1990.
13. Jue D-M, Sherry B, Leudke C, Manogue KR, Cerami A: Processing of newly synthesized cachetin/tumor necrosis factor in endotoxin-stimulated macrophages. Biochemistry 29:8371-8383, 1990.
14. Tracey KJ, Cerami A: Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 9:317-343, 1993.
15. Semmler J, Gebert U, Eisenhut, T, Moeller J, Schonharting MM, Allera A, Endres S: Xanthine derivatives: Comparison between suppression of tumor necrosis factor-α production and inhibition of cAMP phosphodiesterase activity. Immunology 78:520-525, 1993.
16. Semmler J, Wachtel H, Endres S: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 15:409-423, 1993.
17. 9-Tetrahydrocannabinol inhibition of tumor necrosis factor-α: Suppression of posttranslational events. J Pharmacol Exp Ther 267:1558-1565, 1993.
18. Sambrook J, Fritsch EF, Maniaris T: "Molecular Cloning: A Laboratory Manual. 2nd Ed." Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
19. Gonzalo JA, Gonzalez-Garcia, Kalland T, Hedlund G, Martinez-AC, Kroemer G: Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 23:2372-2374, 1993.
20. Han J, Huez G, Beutler B: Interactive effects of the tumor necrosis factor promoter and 3′-untranslated regions. J Immunol 146:1843-1848, 1991.
21. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A: Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 83:1670-1674, 1986.
22. Han J, Brown HR, Beutler B: Endotoxin responsive sequences control cachetin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 171:465-475, 1990.
23. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachetin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 172:391-394, 1990.
24. Nguyen DT, Eskandari MK, DeForge LE, Raiford CL, Strieter RM, Kunkel SL, Remick DG: Cyclosporin A modulation of tumor necrosis factor gene expression and effects in vitro and in vivo. J Immunol 144:3822-3828, 1990.